Showing results (361-370 of 371) with videos related to
Sort By:
Pageof 38
Bioorganic & Medicinal Chemistry Letters|June 7, 2011
Phenyl isoxazole voltage-gated sodium channel blockers: structure and activity relationshipIstvan Macsari, Lars Sandberg, Yevgeni Besidski, et al.Science (New York, N.Y.)|September 1, 1978
Trisodium phosphonoformate, a new antiviral compoundE Helgstrand, B Eriksson, N G Johansson, et al.Bioorganic & Medicinal Chemistry Letters|July 27, 2012
Structure and activity relationship in the (S)-N-chroman-3-ylcarboxamide series of voltage-gated sodium channel blockersInger Kers, Gabor Csjernyik, Istvan Macsari, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptomsA N Wymenga, B Eriksson, P I Salmela, et al.American Journal of Community Psychology|June 26, 2009
Exposure to violence, support needs, adjustment, and motivators among Guatemalan humanitarian aid workersKatharine M Putman, Jeanette I Lantz, Cynthia L Townsend, et al.Bioorganic & Medicinal Chemistry Letters|September 4, 2012
Phenethyl nicotinamides, a novel class of Na(V)1.7 channel blockers: structure and activity relationshipInger Kers, Istvan Macsari, Gabor Csjernyik, et al.Alimentary Pharmacology & Therapeutics|October 18, 2005
Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirinN D Yeomans, A I Lanas, N J Talley, et al.Journal of Medicinal Chemistry|July 10, 2012
3-Oxoisoindoline-1-carboxamides: potent, state-dependent blockers of voltage-gated sodium channel Na(V)1.7 with efficacy in rat pain modelsIstvan Macsari, Yevgeni Besidski, Gabor Csjernyik, et al.Human Molecular Genetics|June 29, 2007
A stop codon mutation in SCN9A causes lack of pain sensationSultan Ahmad, Leif Dahllund, Anders B Eriksson, et al.ESMO Open|December 3, 2025
Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trialJ Capdevila, S Tafuto, M Krogh, et al.Pageof 38